John Stalfort, III Biography and Net Worth



Mr. John Stalfort, III is the Director of Acumen Pharmaceuticals.

What is John A. Stalfort, III's net worth?

The estimated net worth of John A. Stalfort, III is at least $4.05 million as of August 16th, 2023. Mr. Stalfort, III owns 999,381 shares of Acumen Pharmaceuticals stock worth more than $4,047,493 as of March 29th. This net worth evaluation does not reflect any other investments that Mr. Stalfort, III may own. Learn More about John A. Stalfort, III's net worth.

How do I contact John A. Stalfort, III?

The corporate mailing address for Mr. Stalfort, III and other Acumen Pharmaceuticals executives is , , . Acumen Pharmaceuticals can also be reached via phone at 434-297-1000 and via email at [email protected]. Learn More on John A. Stalfort, III's contact information.

Has John A. Stalfort, III been buying or selling shares of Acumen Pharmaceuticals?

John A. Stalfort, III has not been actively trading shares of Acumen Pharmaceuticals in the last ninety days. Most recently, on Tuesday, July 6th, John A. Stalfort III bought 35,000 shares of Acumen Pharmaceuticals stock. The stock was acquired at an average cost of $16.00 per share, with a total value of $560,000.00. Learn More on John A. Stalfort, III's trading history.

Who are Acumen Pharmaceuticals' active insiders?

Acumen Pharmaceuticals' insider roster includes Marc Benioff (CEO), Nathan Fountain (Director), Paul Manning (Director), and John Stalfort, III (Director). Learn More on Acumen Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Acumen Pharmaceuticals?

During the last year, Acumen Pharmaceuticals insiders bought shares 1 times. They purchased a total of 5,161,290 shares worth more than $39,999,997.50. During the last year, insiders at the sold shares 5 times. They sold a total of 73,157 shares worth more than $382,384.76. The most recent insider tranaction occured on January, 19th when CEO Daniel Joseph Oconnell sold 15,200 shares worth more than $52,744.00. Insiders at Acumen Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Acumen Pharmaceuticals.

Information on this page was last updated on 1/19/2024.

John A. Stalfort, III Insider Trading History at Acumen Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/6/2021Buy35,000$16.00$560,000.00View SEC Filing Icon  
See Full Table

John A. Stalfort, III Buying and Selling Activity at Acumen Pharmaceuticals

This chart shows John A Stalfort III's buying and selling at Acumen Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Acumen Pharmaceuticals Company Overview

Acumen Pharmaceuticals logo
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Read More

Today's Range

Now: $4.05
Low: $4.01
High: $4.28

50 Day Range

MA: $3.71
Low: $2.97
High: $4.64

2 Week Range

Now: $4.05
Low: $1.81
High: $11.31

Volume

511,355 shs

Average Volume

418,025 shs

Market Capitalization

$234.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.1